272 related articles for article (PubMed ID: 11465302)
1. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs.
Rahme E; Joseph L; Kong SX; Watson DJ; Pellissier JM; LeLorier J
Pharmacoeconomics; 2001; 19(5 Pt 2):577-88. PubMed ID: 11465302
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
Arthritis Rheum; 2000 Apr; 43(4):917-24. PubMed ID: 10765939
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
4. Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions.
Davis R; Yarker YE; Goa KL
Drugs Aging; 1995 Nov; 7(5):372-93. PubMed ID: 8573992
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
[TBL] [Abstract][Full Text] [Related]
6. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database.
Schnitzer TJ; Kong SX; Mavros PP; Straus WL; Watson DJ
Clin Ther; 2001 Dec; 23(12):1984-98. PubMed ID: 11813933
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis.
Kristiansen IS; Kvien TK; Nord E
Arthritis Rheum; 1999 Nov; 42(11):2293-302. PubMed ID: 10555023
[TBL] [Abstract][Full Text] [Related]
9. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac.
Morant SV; Shield MJ; Davey PG; MacDonald TM
Pharmacoepidemiol Drug Saf; 2002; 11(5):393-400. PubMed ID: 12271881
[TBL] [Abstract][Full Text] [Related]
10. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada.
Zabinski RA; Burke TA; Johnson J; Lavoie F; Fitzsimon C; Tretiak R; Chancellor JV
Pharmacoeconomics; 2001; 19 Suppl 1():49-58. PubMed ID: 11280105
[TBL] [Abstract][Full Text] [Related]
11. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.
Bocanegra TS; Weaver AL; Tindall EA; Sikes DH; Ball JA; Wallemark CB; Geis GS; Fort JG
J Rheumatol; 1998 Aug; 25(8):1602-11. PubMed ID: 9712107
[TBL] [Abstract][Full Text] [Related]
12. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Targownik LE; Metge CJ; Leung S; Chateau DG
Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
[TBL] [Abstract][Full Text] [Related]
13. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.
Maetzel A; Ferraz MB; Bombardier C
Arthritis Rheum; 1998 Jan; 41(1):16-25. PubMed ID: 9433865
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
16. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
17. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
[TBL] [Abstract][Full Text] [Related]
18. Diclofenac/misoprostol. Pharmacoeconomic implications of therapy.
Plosker GL; Lamb HM
Pharmacoeconomics; 1999 Jul; 16(1):85-98. PubMed ID: 10539124
[TBL] [Abstract][Full Text] [Related]
19. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly.
Lanas A; Ferrandez A
Drugs Aging; 2007; 24(2):121-31. PubMed ID: 17313200
[TBL] [Abstract][Full Text] [Related]
20. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients.
Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
Br J Clin Pharmacol; 2001 Aug; 52(2):185-92. PubMed ID: 11488776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
